Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: eCollection Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Drug Utilization* ; Tertiary Care Centers*; Anti-Bacterial Agents/*therapeutic use ; Carbapenems/*pharmacology ; Drug Resistance, Bacterial/*drug effects ; Gram-Negative Bacteria/*drug effects; Acinetobacter baumannii/drug effects ; Anti-Bacterial Agents/administration & dosage ; Carbapenem-Resistant Enterobacteriaceae/drug effects ; Carbapenems/therapeutic use ; Cephalosporins/therapeutic use ; China/epidemiology ; Escherichia coli ; Gram-Negative Bacteria/isolation & purification ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/epidemiology ; Humans ; Klebsiella pneumoniae/drug effects ; Penicillins/therapeutic use ; Prevalence ; Pseudomonas aeruginosa/drug effects ; Quinolones/therapeutic use ; Retrospective Studies

Background: This study aimed to investigate the relationship between the rate of carbapenem-resistant Gram-negative bacteria and antibiotic consumption intensity in 153 tertiary hospitals from China in 2014.
Methods: A retrospective study using national surveillance data from 2014 was conducted. Data on the annual consumption of each antibiotic, as well as the rate of carbapenem-resistant Gram-negative bacteria, were collected from each participating hospital, and the correlation between antibiotic consumption and carbapenem- resistant rate was analyzed.
Results: The overall antibiotic consumption intensity among the hospitals varied between 23.93 and 86.80 defined daily dosages (DDDs) per 100 patient-days (median, 46.30 DDDs per 100 patient-days). Cephalosporins were the most commonly used antibiotic, followed by quinolones, penicillins, and carbapenems, and the rate of carbapenem-resistant Gram-negative bacteria from each hospital varied. The correlations between carbapenem consumption intensity and rate of carbapenem resistance revealed correlation factors of 0.271 for Escherichia coli ( p  < 0.01), 0.427 for Klebsiella pneumoniae ( p  < 0.01), 0.463 for Pseudomonas aeruginosa ( p  < 0.01), and 0.331 for Acinetobacter baumannii ( p  < 0.01).
Conclusions: A significant relationship existed between the carbapenem consumption and the rates of carbapenem-resistant gram negative bacilli. Rational use of carbapenems should be implemented to address the issue of carbapenem resistance in hospitals.
Competing Interests: Given that this study was performed without accessing patient information, approval of the ethics committee was not required.Not applicableThe authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Clin Microbiol Infect. 2014 May;20(5):416-23. (PMID: 24131374)
Microb Drug Resist. 2018 Mar;24(2):190-198. (PMID: 28749714)
Infection. 2017 Aug;45(4):459-467. (PMID: 28265870)
J Clin Pharmacol. 2013 Jan;53(1):96-102. (PMID: 23400749)
Biomed Res Int. 2016;2016:2475067. (PMID: 27274985)
J Antimicrob Chemother. 2017 Nov 1;72(11):3187-3190. (PMID: 28961733)
BMC Infect Dis. 2014 Jan 09;14:13. (PMID: 24405683)
Diagn Microbiol Infect Dis. 2015 Feb;81(2):119-25. (PMID: 25497458)
J Clin Diagn Res. 2015 Feb;9(2):DC08-12. (PMID: 25859453)
J Antimicrob Chemother. 2004 Oct;54(4):821-3. (PMID: 15355942)
Braz J Infect Dis. 2012 Jul-Aug;16(4):351-6. (PMID: 22846123)
Int J Antimicrob Agents. 2005 Dec;26(6):463-72. (PMID: 16280243)
World J Microbiol Biotechnol. 2014 Oct;30(10):2681-7. (PMID: 24964907)
Zentralbl Chir. 2016 Feb;141(1):53-61. (PMID: 24777619)
J Infect Dev Ctries. 2014 Sep 12;8(9):1096-102. (PMID: 25212073)
Antimicrob Resist Infect Control. 2014 Oct 20;3(1):32. (PMID: 25371812)
J Antimicrob Chemother. 2011 Feb;66(2):398-407. (PMID: 21106563)
J Infect Chemother. 2015 Aug;21(8):570-4. (PMID: 26026660)
Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):94-8. (PMID: 26499423)
J Glob Antimicrob Resist. 2017 Mar;8:148-156. (PMID: 28167308)
J Microbiol Immunol Infect. 2015 Oct;48(5):540-4. (PMID: 24685280)
Bacteriol Virusol Parazitol Epidemiol. 2010 Apr-Jun;55(2):179-86. (PMID: 21553483)
Clin Microbiol Infect. 2016 Mar;22 Suppl 1:S9-14. (PMID: 27000156)
J Infect Public Health. 2018 May - Jun;11(3):339-346. (PMID: 29017750)
J Microbiol Immunol Infect. 2017 Oct;50(5):677-683. (PMID: 26188977)
Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29203488)
PLoS One. 2017 Dec 27;12(12):e0190314. (PMID: 29281716)
J Microbiol Immunol Infect. 2016 Feb;49(1):74-82. (PMID: 26586483)
Antimicrob Agents Chemother. 2014 May;58(5):2626-37. (PMID: 24550343)
Ir J Med Sci. 2017 Aug;186(3):733-741. (PMID: 28054236)

Keywords: Acinetobacter baumannii; Carbapenem antibiotic consumption; Carbapenem-resistance; Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa

0 (Anti-Bacterial Agents)
0 (Carbapenems)
0 (Cephalosporins)
0 (Penicillins)
0 (Quinolones)

Date Created: 20181128 Date Completed: 20190930 Latest Revision: 20190930

20221213

PMC6245771

10.1186/s13756-018-0430-1

30479750